Cornerstone gains US rights to Pertzye for EPI due to cystic fibrosis patients

9 May 2013

US specialty pharma company Cornerstone Therapeutics (Nasdaq: CRTX) has entered into an agreement with Digestive Care (DCI) to acquire exclusive US rights to market Pertzye (pancrelipase) for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). Financial terms of the accord were not disclosed.

Pertzye is a unique pancreatic enzyme product and is protected by several US patents. The Pertzye formulation was previously marketed by DCI for more than a decade under the trade name Pancrecarb MS-16. It is estimated that about 90% of patients with CF receive pancreatic enzyme replacement therapy with the therapeutic category experiencing 24% annual growth from 2008-2012.

Adds to CF franchise

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK